Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01261247 · FLOW

Participant flow

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · Source last updated 2022-05-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive oral 40 mg panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Arm I (LBH589)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Ineligible
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        41
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        39
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        2
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive oral 40 mg panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
    id
    FG000
    title
    Arm I (LBH589)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      type
      Ineligible
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        41
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        39
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        2
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice